Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

BACKGROUND: The sustained clinical activity of the BRAF inhibitor vemurafenib (PLX4032/RG7204) in patients with BRAF(V600) mutant melanoma is limited primarily by the development of acquired resistance leading to tumor progression. Clinical trials are in progress using MEK inhibitors following disea...

Full description

Saved in:
Bibliographic Details
Main Authors: Atefi, Mohammad, von Euw, Erika, Attar, Narsis, Ng, Charles, Chu, Connie, Guo, Deliang, Nazarian, Ramin, Chmielowski, Bartosz, Glaspy, John A., Comin-Anduix, Begonya, Mischel, Paul S., Lo, Roger S., Ribas, Antoni
Format: Artigo
Language:Inglês
Published: Public Library of Science 2011
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3237573/
https://ncbi.nlm.nih.gov/pubmed/22194965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0028973
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items